Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 8/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379822 | 0.73 | HSD11B1 (0.50) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL2747473 | 0.70 | HSD11B1 (1.00) | ALDH1A1HSD11B1LMNANPC1RAB9A | |
| SCHEMBL13385743 | 0.69 | HSD11B1 (0.53) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL2747350 | 0.68 | HSD11B1 (0.83) | HSD11B1 | |
| SCHEMBL10940862 | 0.66 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL11825860 | 0.66 | MAT2A (0.48) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL10940832 | 0.66 | HSD11B1 (0.63) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL18912380 | 0.66 | HSD11B1 (0.81) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL11823985 | 0.66 | SMN1; SMN2 (0.45) | ALDH1A1KDM4EHPGDHSD11B1LMNA | |
| SCHEMBL12502536 | 0.65 | PDE2A (1.00) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2086973-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | Amgen Inc., (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008045393-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045393-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2024/4885KDM4E 2389/4885HPGD 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.